Subsidiary Bankruptcy and Deconsolidation (Details) - USD ($)		3 Months Ended
	Apr. 26, 2019	Mar. 31, 2020	Mar. 31, 2019	Oct. 02, 2019	Jul. 02, 2019	Feb. 08, 2019	Feb. 05, 2019
Business Acquisition, Contingent Consideration [Line Items]
Gain (loss) on deconsolidation of subsidiary		$ 0	$ (2,673,000)
DIP Credit Agreement | Debtor in Possession Credit and Security Facility
Business Acquisition, Contingent Consideration [Line Items]
Gain (loss) on deconsolidation of subsidiary		407,000
Payments for debtor in possession financing		407,000
Speciality Pharama
Business Acquisition, Contingent Consideration [Line Items]
Aggregate cash proceeds of intangible assets and remaining inventory	$ 250,000
Speciality Pharama | Internal Revenue Service (IRS)
Business Acquisition, Contingent Consideration [Line Items]
Bankruptcy claims, amount of filed claims likely to be denied		$ 1,937,000		$ 9,302,000	$ 50,695,000
Speciality Pharama | DIP Credit Agreement | Debtor in Possession Credit and Security Facility
Business Acquisition, Contingent Consideration [Line Items]
DIP financing, amount arranged						$ 2,700,000
Specialty Pharma
Business Acquisition, Contingent Consideration [Line Items]
Equity method investments, fair value							$ 0